Equity Analysis

Company News

    J K Pharmachem Ltd
    Industry :  Pharmaceuticals - Indian - Bulk Drugs
    BSE Code
    ISIN Demat
    Book Value()
    500218
    INE335C01018
    -5.96999979019165
    NSE Symbol
    P/E(TTM)
    Mar.Cap( Cr.)
    JKPHARMA
    0
    11.2200002670288
    EPS(TTM)
    Face Value()
    Div & Yield %:
    0
    10
    0
     
H.G.Infra Eng slides after Q2 PAT fall 16% YoY to Rs 81 cr
Nov 12,2024
Revenue from operations declined 5.46% YoY to Rs 902.40 crore in the quarter ended 30 September 2024.

Profit before tax shed 3.02% to Rs 125.23 crore in Q2 FY25 as against Rs 129.13 crore recorded in Q2 FY24.

The company’s total expenses slipped 5.71% YoY to Rs 781.19 crore in Q2 FY25. Employee benefits expense stood at Rs 75.55 crore (up 16.23% YoY) while Finance costs stood at Rs 62.42 crore (up 6.19% YoY) during the period under review.

On half year basis, the company’s consolidated net profit shed 1.29% YoY to Rs 243.30 crore in H1 FY25 as compared to Rs 246.50 crore recorded in H1 FY24. Revenue from operations rose 5.41% YoY to Rs 2,430.44 crore in H1 FY25.

H.G. Infra Engineering is primarily involved in the construction of roads and highways in Odisha, Telangana, Rajasthan, Delhi, Andhra Pradesh, Haryana, and Uttar Pradesh. HGIEL is accredited AA class by the Public Works Department (PWD) of the Government of Rajasthan (GoR) and is registered as an SS class contractor by the Military Engineer Services (MES).